<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">M Justin Coffey, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter P Roy-Byrne, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen Marder, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 15, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H6713675"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Catatonia is a behavioral syndrome marked by an inability to move normally despite full physical capacity to do so. The syndrome occurs in the context of many underlying psychiatric and general medical disorders [<a href="#rid1">1</a>]. Within psychiatric nosology, catatonia is not conceptualized as a separate diagnostic entity [<a href="#rid2">2,3</a>]. Rather, the term catatonia is used to specify a subtype of the underlying disorder, similar to the term “psychotic features.” (However, some experts view catatonia as a syndrome that warrants a stand-alone diagnosis [<a href="#rid4">4</a>].)</p><p>Recognizing catatonia is important because it may be caused or exacerbated by treatment of the underlying disorder. As an example, antipsychotic drugs used for bipolar or psychotic disorders may worsen catatonia [<a href="#rid5">5</a>].</p><p>This topic reviews the epidemiology, pathogenesis, clinical features, assessment, and diagnosis of catatonia, as well as the disorders that can progress to catatonia. The treatment and prognosis of catatonia are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15869.html" rel="external">"Catatonia: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H6713689"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The estimated incidence of catatonia has been studied primarily in acutely ill psychiatric inpatients [<a href="#rid3">3</a>]. The incidence is approximately 10 percent, but estimates range from 5 to 20 percent, based upon prospective studies conducted for one to twelve months at individual psychiatric units [<a href="#rid6">6-14</a>]. The range is probably due in part to differences in study methods, including how catatonia was defined. The syndrome may go unrecognized, leading to the false conclusion that it is rare. In a Dutch study of 139 acutely psychotic inpatients, the treatment team diagnosed catatonia nine times less often than the research team (2 versus 18 percent of patients) [<a href="#rid8">8</a>].</p><p>It is not clear if there are any sociodemographic risk factors for catatonia. Catatonia seems to occur more commonly in patients with unipolar major depression or bipolar disorder, compared with other disorders [<a href="#rid6">6</a>]. In addition, catatonia may perhaps occur more often in patients with prior episodes. (See <a class="local">'Underlying disorders'</a> below and <a class="local">'Recurrence'</a> below.)</p><p class="headingAnchor" id="H6713696"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Catatonia occurs in the context of an underlying psychiatric or general medical disorder, and treatments that are used for these underlying disorders may cause or exacerbate catatonia. As an example, antipsychotic drugs used for bipolar or psychotic disorders may worsen catatonia [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/15869.html" rel="external">"Catatonia: Treatment and prognosis", section on 'Avoid dopamine blocking drugs'</a>.)</p><p>The pathophysiology of catatonia is unknown. Neurobiologic correlates of catatonia have been identified, but it is not clear if these findings represent etiologic causes or sequelae of the disorder [<a href="#rid15">15</a>].</p><p>Neurobiologic studies have led to a hypothesis that catatonia involves pathways that connect the basal ganglia with the cortex and thalamus [<a href="#rid16">16</a>]. Neuropathologic studies of patients with catatonic schizophrenia have found alterations in the basal ganglia (caudate nucleus, nucleus accumbens, and pallidum) and thalamus [<a href="#rid17">17</a>]. Neuroimaging studies suggest that catatonia may possibly involve functional alterations in the prefrontal, orbitofrontal, and parietal cortices [<a href="#rid18">18,19</a>]. In addition, neuropsychologic tests of remitted catatonic patients found a deficit in visual-spatial abilities that may involve right parietal cortex function [<a href="#rid17">17,20</a>]. Neurotransmitter studies suggest that catatonia may be associated with decreased activity at gamma-aminobutyric acid A and dopamine D2 receptors, and increased activity at N-methyl-D-aspartate receptors [<a href="#rid19">19,21</a>].</p><p>Some patients may possibly have a genetic predisposition to catatonia. Preliminary evidence suggests that genes on chromosomes 15 and 22 may be linked to the periodic form of catatonia [<a href="#rid22">22-25</a>]. (See <a class="local">'Other forms'</a> below.)</p><p class="headingAnchor" id="H6713703"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>The core feature of catatonia is a motor disturbance in which patients are unable to move normally despite full physical capacity in the limbs and trunk [<a href="#rid1">1</a>]. The disturbance can range from marked reduction in movements to marked agitation. Starting, stopping, and planning movement can be impaired, and motor behavior may be repetitive, purposeless, impervious to external stimuli, and contrary to intent [<a href="#rid11">11</a>].</p><p>Small prospective studies of catatonia and case series have found that catatonia is marked by heterogeneous signs that are observed or elicited  (<a class="graphic graphic_table graphicRef53391" href="/z/d/graphic/53391.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef66229" href="/z/d/graphic/66229.html" rel="external">table 2</a>); the most common are [<a href="#rid1">1,11,26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Immobility (hypokinesis or akinesis)</p><p class="bulletIndent1"><span class="glyph">●</span>Mutism</p><p class="bulletIndent1"><span class="glyph">●</span>Stupor (decreased alertness and response to stimuli)</p><p class="bulletIndent1"><span class="glyph">●</span>Negativism (resistance to all instructions or all attempts to be moved)</p><p class="bulletIndent1"><span class="glyph">●</span>Waxy flexibility</p><p class="bulletIndent1"><span class="glyph">●</span>Posturing</p><p class="bulletIndent1"><span class="glyph">●</span>Excessive, purposeless motor activity (excitement)</p><p class="bulletIndent1"><span class="glyph">●</span>Staring</p><p class="bulletIndent1"><span class="glyph">●</span>Echophenomena</p><p class="bulletIndent2"><span class="glyph">•</span>Echolalia – Senseless repetition of another person's utterances</p><p class="bulletIndent2"><span class="glyph">•</span>Echopraxia – Senseless repetition of another person's movements</p><p></p><p>Onset of catatonia can be either acute or insidious [<a href="#rid1">1,9</a>]. Following remission, some patients cannot recall their experience during the episode, whereas others describe an awareness of their activity and the inability to communicate [<a href="#rid27">27</a>].</p><p>Catatonia occurs in patients who are severely ill with an underlying psychiatric or general medical disorder [<a href="#rid3">3,28</a>] (see <a class="local">'Underlying disorders'</a> below). Thus, catatonia is typically seen in hospitalized patients.</p><p class="headingAnchor" id="H14470929"><span class="h2">Subtypes</span><span class="headingEndMark"> — </span>There are several subtypes of catatonia, based upon the specific nature of the movement disturbance and other associated features [<a href="#rid1">1,29,30</a>]. Although psychiatric nosology does not formally recognize the subtypes as diagnostic entities, the subtypes are clinically useful constructs that are consistent with the symptoms that constitute a diagnosis of catatonia (See <a class="local">'Psychiatric nosology'</a> below.)</p><p>The behavioral phenotype of catatonia exists on a continuum between retarded and excited subtypes, depending upon the motor disturbance. In addition, the severity of catatonia exists on a continuum between nonmalignant and malignant, depending upon other associated features. The three principal forms of catatonia in order of incidence are retarded, excited, and malignant. While a factor-analytic study of 314 psychotic patients supported separation of retarded and excited catatonia as subtypes [<a href="#rid31">31</a>], patients can exhibit signs of both subtypes concurrently [<a href="#rid32">32</a>]. Subtypes are not necessarily stable during a catatonic episode, and patients may transition from retarded to excited catatonia or vice versa [<a href="#rid33">33,34</a>]. In addition, retarded and excited catatonia can each progress to malignant catatonia; alternatively, malignant catatonia can occur de novo.</p><p class="headingAnchor" id="H14470936"><span class="h3">Retarded catatonia</span><span class="headingEndMark"> — </span>The retarded form of catatonia is characterized by mutism, inhibited movement, posturing, negativism, and staring [<a href="#rid1">1,10</a>]. Postures may be mundane (eg, sitting or standing in the same position for hours) or unusual (eg, head raised above the bed as if on a pillow). Response to voice and noxious stimuli is decreased. Although speech and spontaneous movements are reduced, some patients appear to be alert and aware of the environment. In more severe cases, eating and drinking may cease and stupor and incontinence may occur [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H3688700361"><span class="h3">Excited catatonia</span><span class="headingEndMark"> — </span>Excited catatonia is characterized by excessive and purposeless motor activity in both the upper and lower limbs (hyperkinesis), restlessness, stereotypy, impulsivity, frenzy, and combativeness [<a href="#rid1">1,10</a>]. Delirium may occur in severe cases, and the excess motor activity may cause self-injury or harm to others.</p><p class="headingAnchor" id="H14470950"><span class="h3">Malignant catatonia</span><span class="headingEndMark"> — </span>Malignant catatonia (also called lethal catatonia) is a life-threatening condition that is characterized by fever (less likely in older patients), autonomic instability (labile or elevated blood pressure, tachycardia, tachypnea, and diaphoresis), delirium, and rigidity [<a href="#rid1">1,16</a>]. The syndrome is typically fulminant and progresses rapidly within a few days [<a href="#rid35">35</a>]. Common but nonspecific laboratory findings include leukocytosis, elevated creatine kinase, and low serum iron [<a href="#rid16">16,36</a>]. Signs of malignant catatonia overlap with signs of the neuroleptic malignant syndrome (NMS). (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H14470957"><span class="h3">Other forms</span><span class="headingEndMark"> — </span>Other, infrequent forms of catatonia may occur [<a href="#rid1">1</a>]. One example is periodic catatonia, which is marked by waxing and waning of catatonic signs [<a href="#rid29">29</a>] or periods of retarded catatonia alternating with excited catatonia [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H1662065"><span class="h2">Underlying disorders</span><span class="headingEndMark"> — </span>Psychiatric nosology does not conceptualize catatonia as a specific disease; rather, catatonia is a syndrome that occurs in the context of an underlying psychiatric or general medical illness [<a href="#rid2">2,3,16</a>]. Multiple underlying conditions may be present in the same catatonic patient [<a href="#rid32">32,37,38</a>]. However, it is not known if comorbidity increases the risk of catatonia. None of the underlying disorders appear to be associated with a specific catatonic sign or subtype [<a href="#rid9">9,32</a>].</p><p>Although catatonia can occur in the context of many mental disorders, it is most often found in [<a href="#rid3">3,39-42</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Bipolar I disorder</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bipolar II disorder</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unipolar major depression (major depressive disorder)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psychotic disorders</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Schizophrenia</p><p class="bulletIndent2"><span class="glyph">•</span>Schizoaffective disorder</p><p class="bulletIndent2"><span class="glyph">•</span>Brief psychotic disorder</p><p class="bulletIndent2"><span class="glyph">•</span>Schizophreniform disorder</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autism spectrum disorder</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Delirium</p><p></p><p>Many general medical disorders can also lead to catatonia. A review of case reports found that catatonia occurred in more than 100 general medical conditions [<a href="#rid32">32</a>]; these included infectious, metabolic, neurologic, and rheumatologic disorders [<a href="#rid1">1,3,43,44</a>]. In addition, a study of 136 patients treated on an intensive care unit with mechanical ventilation and/or vasopressors found that catatonia was present in approximately 35 percent [<a href="#rid45">45</a>].</p><p>On acute inpatient psychiatric units, catatonia most frequently occurs in the context of bipolar disorder or unipolar major depression [<a href="#rid6">6,30,39</a>]. A study of 148 patients with catatonia found that the underlying condition was bipolar disorder or unipolar major depression in 46 percent of patients, psychotic disorder in 26 percent, general medical condition in 20 percent, and another psychiatric disorder in 8 percent of patients [<a href="#rid46">46</a>]. Other reviews have found a similar distribution of underlying diagnoses [<a href="#rid47">47</a>].</p><p>The presence of catatonia reflects the severity of the patient’s underlying illness. As an example, a study of 148 catatonic patients found that nearly 75 percent were concurrently psychotic [<a href="#rid46">46</a>].</p><p>Treatments that are used for the underlying disorder may cause or exacerbate catatonia (eg, antipsychotic drugs used for bipolar or psychotic disorders may worsen catatonia) [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/15869.html" rel="external">"Catatonia: Treatment and prognosis", section on 'Avoid dopamine blocking drugs'</a>.)</p><p class="headingAnchor" id="H2637666813"><span class="h2">Recurrence</span><span class="headingEndMark"> — </span>Patients who recover from catatonic episodes may suffer recurrences. A retrospective study of patients with bipolar disorder and catatonia (n = 26) found that a prior history of catatonia was present in 38 percent [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H85675547"><span class="h1">ASSESSMENT</span><span class="headingEndMark"> — </span>Signs of catatonia can be observed or elicited  (<a class="graphic graphic_table graphicRef53391" href="/z/d/graphic/53391.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef66229" href="/z/d/graphic/66229.html" rel="external">table 2</a>) [<a href="#rid28">28</a>]. Clinicians may overlook these signs because of the severity of associated psychopathology (eg, psychosis). In addition, common signs of catatonia such as mutism, posturing, and rigidity may be absent; many catatonic patients speak and move about. Thus, patients exhibiting only one apparent catatonic sign should be examined for others.</p><p>For patients with an underlying psychiatric disorder, the motor dysregulation of catatonia can be similar to the underlying psychopathology. As an example, the increased motor activity and impulsivity observed in mania may progress to excited catatonia. Mania uncomplicated by catatonia is marked by goal-directed activity and intact cognition. By contrast, activity in catatonia is often repetitive and not goal-directed. As another example, the psychomotor retardation, anergia, anhedonia, and anorexia observed in major depression may resemble retarded catatonia. The hypokinesis and refusal to eat or drink that characterize severe depression may be catatonic signs, and should prompt an assessment for other catatonic signs. Clinical features that often occur in depression not complicated by catatonia include suicidality, sleep disturbance, and feelings of worthlessness, guilt, helplessness, and hopelessness. In addition, catatonia can be distinguished by additional motor signs, such as posturing, rigidity, and negativism, as well as a positive response to the <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> challenge test. (See <a class="local">'Underlying disorders'</a> above and <a class="local">'Lorazepam challenge'</a> below.)</p><p>Rating scales have been used for research purposes to systematically examine patients at the initial assessment and quantify progress during treatment, but their utility for routine clinical care is not well-established [<a href="#rid26">26,46,49</a>]. The most widely used measure is the Bush-Francis Catatonia Rating Scale, which is a 23-item rating scale with good inter-rater reliability (0.93) and construct validity; the first 14 items can be used to screen for catatonia [<a href="#rid50">50</a>]. Each item is defined, the procedure for rating each item is described, and the scale appears to be sensitive to clinical change [<a href="#rid30">30</a>]. The Northoff Catatonia Scale and the Kanner Catatonia Scale are reasonable alternatives [<a href="#rid51">51,52</a>].</p><p>There is no laboratory test specific for catatonia. However, malignant catatonia is associated with non-specific test results that include leukocytosis, increased creatine kinase, and low serum iron  (<a class="graphic graphic_table graphicRef57370" href="/z/d/graphic/57370.html" rel="external">table 3</a>) [<a href="#rid36">36,53-55</a>].</p><p>The underlying disorder may be unknown in some patients with catatonia, in which case the initial clinical evaluation should include the following [<a href="#rid9">9,32,46</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Psychiatric and general medical history.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mental status and physical examination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory tests – Tests should be guided by the symptoms, history, and findings on the physical examination. Patients with an established underlying disorder (eg, unipolar major depression with psychotic features) may not need any tests.</p><p></p><p>Catatonic stupor and mutism may preclude assessing the patient for symptoms of the underlying disorder. However, family and friends can often compensate for the patient’s inability to provide a history. After catatonia resolves, the patient should be re-evaluated for psychopathology or a general medical disorder. (See  <a class="medical medical_review" href="/z/d/html/1721.html" rel="external">"Unipolar depression in adults: Assessment and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/14642.html" rel="external">"Bipolar disorder in adults: Clinical features"</a> and  <a class="medical medical_review" href="/z/d/html/6962.html" rel="external">"Schizophrenia in adults: Clinical features, assessment, and diagnosis"</a>.)</p><p class="headingAnchor" id="H4567794"><span class="h2">Lorazepam challenge</span><span class="headingEndMark"> — </span>Nearly every catatonic patient is treated initially with <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> or another benzodiazepine (patients with malignant catatonia may be quickly switched to electroconvulsive therapy); the response to the first one or two doses can help make the diagnosis of catatonia. Case series suggest using an intravenous (IV) bolus of lorazepam 1 to 2 mg [<a href="#rid32">32</a>]. IV administration allows for rapid, complete absorption, although intramuscular (IM) injections and oral administration have also been used [<a href="#rid30">30,56</a>]. Intravenous benzodiazepines should be injected or infused slowly. In addition, clinicians should be cognizant of concomitant drugs that can cause sedation or respiratory depression, eg, opioids. Benzodiazepines cause varying degrees of motor incoordination and increase the risk of falls [<a href="#rid12">12</a>].</p><p>Partial, temporary relief of signs 5 to 10 minutes after IV administration of <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> is consistent with a diagnosis of catatonia [<a href="#rid1">1,29</a>]. If there is no change and the patient remains awake with stable vital signs, a second dose is given, and the patient is examined within 5 to 10 minutes, although observation can continue for longer periods. A negative response does not rule out catatonia, and occurs in approximately 20 percent or more of catatonic patients.</p><p>Reasonable alternatives to <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> are available. A randomized trial that compared a single dose of oral <a class="drug drug_general" data-topicid="9726" href="/z/d/drug information/9726.html" rel="external">oxazepam</a> 60 mg with a single dose of oral lorazepam 2 mg in 17 patients found that the benefit of each drug was comparable [<a href="#rid57">57</a>]. In case reports, oral <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">zolpidem</a> 10 mg was useful [<a href="#rid26">26,37,58-60</a>].</p><p>The treatment of catatonia is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15869.html" rel="external">"Catatonia: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H6713717"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>A minimum of two to four signs for at least several hours is required to make the diagnosis of catatonia  (<a class="graphic graphic_table graphicRef53391" href="/z/d/graphic/53391.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef66229" href="/z/d/graphic/66229.html" rel="external">table 2</a>) [<a href="#rid1">1,12,26,50</a>]. However, neither the number of catatonic features nor their duration is established, and no one sign is pathognomonic [<a href="#rid47">47</a>]. A positive <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> challenge test can help verify the diagnosis. (See <a class="local">'Lorazepam challenge'</a> above.)</p><p class="headingAnchor" id="H13003965"><span class="h2">Psychiatric nosology</span><span class="headingEndMark"> — </span>According to psychiatric nosology, catatonia is not a separate, specific disease; rather, catatonia is a behavioral syndrome that is diagnosed in patients who are ill with an underlying psychiatric and/or general medical disorder [<a href="#rid2">2,3</a>]. In the American Psychiatric Association's Diagnostic and Statistical Manual, Fifth Edition, Text Revision (DSM-5-TR), the term catatonia is used to specify a subtype of the underlying disorder, similar to the term “psychotic features” [<a href="#rid3">3</a>]. The underlying psychiatric disorders that can give rise to catatonia include autism spectrum disorder, bipolar disorders, psychotic disorders, and unipolar major depression.</p><p>In DSM-5-TR, criteria for catatonia are met when the clinical picture is dominated by at least three of the following [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Stupor (decreased psychomotor activity or decreased reactivity to the environment)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Catalepsy (passively allowing the examiner to position the body or a body part)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Waxy flexibility (slight, even resistance to positioning by the examiner, as in bending a candle)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mutism (lack of verbal response; not applicable to patients with an established aphasia)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Negativism (motiveless resistance to instructions or external stimuli)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Posturing (voluntarily maintaining a position of the body or a body part against gravity for a long time)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mannerisms (odd movements)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stereotypy (repetitive movements that are not goal directed and often are awkward or stiff)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Agitation or excessive motor activity that is purposeless and not influenced by external stimuli</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grimacing</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Echolalia (mimicking another person’s speech)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Echopraxia (mimicking another person’s movements)</p><p></p><p class="headingAnchor" id="H6713738"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Signs of catatonia can overlap with signs of other disorders; in particular, malignant catatonia may resemble the neuroleptic malignant syndrome (NMS) [<a href="#rid5">5,61</a>]. Both disorders present with fever, autonomic instability, rigidity, and delirium. Patients who present with these signs should be assessed with neuroimaging and a lumbar puncture to rule out central nervous system and systemic infection.</p><p>The differential diagnosis of catatonia includes a number of conditions, some of which can cause catatonia (eg, delirium, stroke, and nonconvulsive status epilepticus) [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuroleptic malignant syndrome</strong> – The neuroleptic malignant syndrome (NMS) and malignant catatonia are life-threatening disorders with similar clinical features. Both disorders can present with delirium, autonomic instability, fever, and rigidity [<a href="#rid61">61,62</a>]. In addition, an elevated creatinine kinase and white blood count and low serum iron are common to NMS and malignant catatonia. A review of 292 cases of malignant catatonia found that the clinical features were indistinguishable from NMS in more than 20 percent of cases [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">"Neuroleptic malignant syndrome", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1">Many authorities consider NMS a drug-induced form of malignant catatonia, based upon their overlapping clinical features as well as similarities in the hypothesized pathophysiology for each disorder [<a href="#rid1">1,5,9,11,16,21,26,62,64</a>]. In addition, discontinuing antipsychotics and starting benzodiazepines can be helpful for both NMS and malignant catatonia, and electroconvulsive therapy can benefit patients with either disorder even after failed pharmacotherapy [<a href="#rid1">1,61</a>].</p><p></p><p class="bulletIndent1">However, it is not established that NMS is a subtype of catatonia [<a href="#rid18">18,46</a>]. Malignant catatonia can present with signs (eg, impulsivity, posturing, and repetitive stereotypic movements) that are not generally observed in NMS [<a href="#rid46">46,65,66</a>], affective symptoms that can occur in catatonia do not seem to be as prominent in NMS [<a href="#rid18">18</a>], and laboratory abnormalities that occur in NMS may not occur as consistently in patients with malignant catatonia [<a href="#rid46">46</a>]. Some authorities hypothesize that NMS and malignant catatonia have overlapping but distinct pathophysiologic mechanisms [<a href="#rid18">18</a>]. Establishing the diagnosis of NMS can lead to treatment that differs in some respects from that of catatonia [<a href="#rid61">61,63</a>], although some authorities recommend a common and consistent therapeutic approach [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">"Neuroleptic malignant syndrome", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serotonin syndrome</strong> – Serotonin syndrome and malignant catatonia can both present with delirium, autonomic instability, hyperthermia, and rigidity. Distinguishing features of the serotonin syndrome include ingestion of a serotonergic drug such as an SSRI, and the prominence of hyperreflexia, myoclonus, nausea, vomiting, and diarrhea. Some authorities view the serotonin syndrome as a form of catatonia, due to similarities in presenting signs and response to specific treatments [<a href="#rid67">67</a>]. (See  <a class="medical medical_review" href="/z/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignant hyperthermia</strong> – Malignant hyperthermia and malignant catatonia can both present with autonomic instability, hyperthermia, and rigidity. Malignant hyperthermia is a rare genetic disorder that occurs in susceptible patients exposed to an inhalational anesthetic (eg, halothane) or a depolarizing muscle relaxant (eg, <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a>). The distinguishing feature of malignant hyperthermia is its clinical setting, and various procedures are used to diagnose it (muscle contracture testing, muscle biopsy, and genetic testing). (See  <a class="medical medical_review" href="/z/d/html/401.html" rel="external">"Malignant hyperthermia: Diagnosis and management of acute crisis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Akinetic mutism</strong> – Akinetic mutism and catatonia may both manifest with immobility, mutism, and waxy flexibility. However, akinetic mutism does not include posturing, echolalia, or echopraxia; is not responsive to benzodiazepines; and the lesions to the prefrontal or premotor areas that cause akinetic mutism should be detectable with neuroimaging. (See  <a class="medical medical_review" href="/z/d/html/5104.html" rel="external">"Stupor and coma in adults", section on 'Akinetic mutism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonconvulsive status epilepticus</strong> – Nonconvulsive status epilepticus and catatonia can both present with stupor and respond positively to benzodiazepines. Nonconvulsive status epilepticus may be distinguished by the presence of subtle rhythmic twitching and ocular movement abnormalities, and is diagnosed by epileptic activity on the electroencephalogram (EEG). By contrast, catatonia is associated with either a normal EEG or diffuse, nonspecific changes (eg, slowing). (See  <a class="medical medical_review" href="/z/d/html/14103.html" rel="external">"Nonconvulsive status epilepticus: Classification, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Locked-in syndrome</strong> – Locked-in syndrome is characterized by immobility and mutism. However, no other signs of catatonia are present, neuroimaging typically reveals brainstem lesions, and locked-in patients usually attempt to communicate with eye movements and blinking, whereas catatonic patients are not motivated to communicate. (See  <a class="medical medical_review" href="/z/d/html/1099.html" rel="external">"Locked-in syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stiff-person syndrome </strong>– Stiff-person syndrome is marked by rigidity and a positive response to a benzodiazepine, and autonomic instability may occur as well, all of which may occur in catatonia. However, stiff-person syndrome is generally accompanied by a fixed deformity of the spine and anti-glutamic acid decarboxylase antibodies, which are not observed in catatonia. In addition, catatonic signs such as mutism and posturing are not part of stiff-person syndrome. (See  <a class="medical medical_review" href="/z/d/html/5131.html" rel="external">"Stiff-person syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parkinson disease</strong> – Retarded catatonia and late-stage untreated Parkinson disease may both present with immobility, rigidity, and decreased speech output. In addition, major depression can occur in Parkinson disease and may underlie catatonia. However, catatonia often includes odd postures and a positive response to benzodiazepines, whereas distinguishing features of Parkinson disease include rest tremor, postural instability, and a positive response to levodopa. (See  <a class="medical medical_review" href="/z/d/html/4903.html" rel="external">"Clinical manifestations of Parkinson disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stroke</strong> – Stroke can manifest with mutism, but focal neurologic signs and positive findings on neuroimaging are often present as well, and other signs of catatonia are absent. (See  <a class="medical medical_review" href="/z/d/html/1083.html" rel="external">"Overview of the evaluation of stroke"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delirium</strong> – Catatonia may include periods of delirium, and delirium may include some features of catatonia. A study of 136 critically ill patients on mechanical ventilation and/or vasopressors found that catatonia plus delirium were both present in approximately 30 percent [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1">Patients with delirium and catatonia present with both stupor (decreased alertness and response to stimuli), hypokinesis or hyperkinesis, and limited speech output, but catatonia is usually accompanied by other distinguishing features, including posturing, rigidity, and negativism, as well as a positive response to the <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> challenge test. (See  <a class="medical medical_review" href="/z/d/html/4824.html" rel="external">"Diagnosis of delirium and confusional states"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dementia</strong> – End-stage dementia and catatonia may both manifest with mutism and hypokinesis. However, catatonia is usually accompanied by other distinguishing features, including posturing, rigidity, negativism, and a positive response to the <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> challenge test.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elective mutism</strong> – Elective mutism is the failure to speak in an otherwise vigilant patient, who may selectively refuse to speak with some individuals and speak with others. The disorder is usually accompanied by a personality disorder, preexisting stressor, and no other signs of catatonia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis</strong> – Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is an autoimmune disorder with prominent neuropsychiatric symptoms, including catatonia in approximately 40 percent of patients [<a href="#rid68">68</a>]. This form of encephalitis may rapidly progress to seizures, hypoventilation, and coma.</p><p></p><p class="bulletIndent1">Anti-NMDA receptor encephalitis and catatonia both can include stupor and motor disturbances; in addition, both anti-NMDA receptor encephalitis and the malignant subtype of catatonia can present with autonomic instability. However, catatonia can be distinguished from this form of encephalitis by the presence of other features, including waxy flexibility, staring, and negativism, as well as a positive response to the <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> challenge test. (See  <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'Anti-NMDA receptor encephalitis'</a>.)</p><p></p><p class="headingAnchor" id="H1553725592"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116503.html" rel="external">"Society guideline links: Depressive disorders"</a>.)</p><p class="headingAnchor" id="H6713745"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The estimated incidence of catatonia in acutely ill psychiatric inpatients is approximately 10 percent. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Catatonia is a behavioral syndrome that is marked by an inability to move normally despite full physical capacity to do so. The syndrome occurs in the context of an underlying psychiatric and/or general medical disorder. Relatively common signs of catatonia include immobility, mutism, and excessive, purposeless motor activity. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subtypes of catatonia</strong> – The three principal subtypes of catatonia are retarded, excited, and malignant. Patients can exhibit signs of more than one subtype, and subtypes are not necessarily stable during a catatonic episode. (See <a class="local">'Subtypes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Underlying psychiatric disorders</strong> – The most common underlying psychopathology is bipolar disorder, unipolar major depression, psychotic disorder, and autism spectrum disorder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment</strong> – Signs of catatonia can be either observed  (<a class="graphic graphic_table graphicRef53391" href="/z/d/graphic/53391.html" rel="external">table 1</a>) or elicited  (<a class="graphic graphic_table graphicRef66229" href="/z/d/graphic/66229.html" rel="external">table 2</a>). The initial clinical evaluation for determining the underlying disorder should include a history, mental status and physical examination, and laboratory tests guided by symptoms and findings on examination. (See <a class="local">'Assessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lorazepam</strong><strong> challenge</strong> – An intravenous (IV) bolus of <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> 1 to 2 mg can help diagnose catatonia. Partial, temporary relief of signs 5 to 10 minutes after IV administration of lorazepam is consistent with a diagnosis of catatonia. If there is no change, a second dose is given. A negative response does not rule out catatonia, and occurs in approximately 20 percent or more of catatonic patients. (See <a class="local">'Lorazepam challenge'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of catatonia requires a minimum of two to four signs  (<a class="graphic graphic_table graphicRef53391" href="/z/d/graphic/53391.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef66229" href="/z/d/graphic/66229.html" rel="external">table 2</a>) for at least several hours. However, neither the number of catatonic features nor their duration is established. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Signs of catatonia can overlap with signs of other disorders; in particular, malignant catatonia resembles the neuroleptic malignant syndrome (NMS). Both are life-threatening disorders that can present with delirium, autonomic instability, fever, and rigidity.</p><p></p><p class="bulletIndent1">The differential diagnosis of catatonia also includes the serotonin syndrome, malignant hyperthermia, akinetic mutism, nonconvulsive status epilepticus, locked-in syndrome, stiff-person syndrome, Parkinson disease, stroke, delirium, dementia, elective mutism, and anti-N-methyl-D-aspartate receptor encephalitis. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fink M, Taylor MA. The catatonia syndrome: forgotten but not gone. Arch Gen Psychiatry 2009; 66:1173.</a></li><li class="breakAll">The ICD-10 Classification of Mental and Behavioural Disorders: Clinical descriptions and diagnostic guidelines. World Health Organization. http://www.who.int/classifications/icd/en/bluebook.pdf (Accessed on October 29, 2013).</li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision, American Psychiatric Association, Washington, D.C. 2022.</li><li><a class="nounderline abstract_t">Fink M. Catatonia from its creation to DSM-V: Considerations for ICD. Indian J Psychiatry 2011; 53:214.</a></li><li><a class="nounderline abstract_t">Lee JW. Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome. J Clin Psychopharmacol 2010; 30:3.</a></li><li><a class="nounderline abstract_t">Taylor MA, Fink M. Catatonia in psychiatric classification: a home of its own. Am J Psychiatry 2003; 160:1233.</a></li><li><a class="nounderline abstract_t">Francis A, Fink M, Appiani F, et al. Catatonia in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. J ECT 2010; 26:246.</a></li><li><a class="nounderline abstract_t">van der Heijden FM, Tuinier S, Arts NJ, et al. Catatonia: disappeared or under-diagnosed? Psychopathology 2005; 38:3.</a></li><li class="breakAll">Freudenreich O, Nejad SH, Francis A, Fricchione GL. Psychosis, mania, and catatonia. In: Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL (Ed), American Psychiatric Publishing, Washington, DC 2011. p.219.</li><li><a class="nounderline abstract_t">Chalasani P, Healy D, Morriss R. Presentation and frequency of catatonia in new admissions to two acute psychiatric admission units in India and Wales. Psychol Med 2005; 35:1667.</a></li><li><a class="nounderline abstract_t">Zisselman MH, Jaffe RL. ECT in the treatment of a patient with catatonia: consent and complications. Am J Psychiatry 2010; 167:127.</a></li><li><a class="nounderline abstract_t">Rosebush PI, Hildebrand AM, Furlong BG, Mazurek MF. Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry 1990; 51:357.</a></li><li><a class="nounderline abstract_t">Ungvari GS, Leung CM, Wong MK, Lau J. Benzodiazepines in the treatment of catatonic syndrome. Acta Psychiatr Scand 1994; 89:285.</a></li><li><a class="nounderline abstract_t">Seethalakshmi R, Dhavale S, Suggu K, Dewan M. Catatonic syndrome: importance of detection and treatment with lorazepam. Ann Clin Psychiatry 2008; 20:5.</a></li><li><a class="nounderline abstract_t">Dhossche DM, Stoppelbein L, Rout UK. Etiopathogenesis of catatonia: generalizations and working hypotheses. J ECT 2010; 26:253.</a></li><li class="breakAll">Mann SC, Caroff SN, Campbell EC, et al. Malignant catatonia. In: Current Clinical Neurology: Movement Disorder Emergencies: Diagnosis and Treatment, Frucht SI, Fahn S (Eds), Humana Press, Totowa, NJ 2005. p.53.</li><li><a class="nounderline abstract_t">Northoff G. What catatonia can tell us about "top-down modulation": a neuropsychiatric hypothesis. Behav Brain Sci 2002; 25:555.</a></li><li><a class="nounderline abstract_t">Northoff G. Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology. J Neural Transm (Vienna) 2002; 109:1453.</a></li><li><a class="nounderline abstract_t">Northoff G. Brain imaging in catatonia: current findings and a pathophysiologic model. CNS Spectr 2000; 5:34.</a></li><li><a class="nounderline abstract_t">Northoff G, Steinke R, Nagel DCzerwenka C, et al. Right lower prefronto-parietal cortical dysfunction in akinetic catatonia: a combined study of neuropsychology and regional cerebral blood flow. Psychol Med 2000; 30:583.</a></li><li><a class="nounderline abstract_t">Carroll BT. The universal field hypothesis of catatonia and neuroleptic malignant syndrome. CNS Spectr 2000; 5:26.</a></li><li><a class="nounderline abstract_t">Meyer J, Huberth A, Ortega G, et al. A missense mutation in a novel gene encoding a putative cation channel is associated with catatonic schizophrenia in a large pedigree. Mol Psychiatry 2001; 6:302.</a></li><li><a class="nounderline abstract_t">Stöber G. Genetic predisposition and environmental causes in periodic and systematic catatonia. Eur Arch Psychiatry Clin Neurosci 2001; 251 Suppl 1:I21.</a></li><li><a class="nounderline abstract_t">Stöber G, Pfuhlmann B, Nürnberg G, et al. Towards the genetic basis of periodic catatonia: pedigree sample for genome scan I and II. Eur Arch Psychiatry Clin Neurosci 2001; 251 Suppl 1:I25.</a></li><li><a class="nounderline abstract_t">Stöber G, Seelow D, Rüschendorf F, et al. Periodic catatonia: confirmation of linkage to chromosome 15 and further evidence for genetic heterogeneity. Hum Genet 2002; 111:323.</a></li><li><a class="nounderline abstract_t">Francis A. Catatonia: diagnosis, classification, and treatment. Curr Psychiatry Rep 2010; 12:180.</a></li><li class="breakAll">Lewis S, Escalona PR, Keith SJ. Phenomenology of schizophrenia. In: Kaplan &amp; Sadock's Comprehensive Textbook of Psychiatry, Ninth Edition, Sadock BJ, Sadock VA, Ruiz P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Vol I, p.1433.</li><li><a class="nounderline abstract_t">Fink M, Taylor MA. Catatonia: subtype or syndrome in DSM? Am J Psychiatry 2006; 163:1875.</a></li><li><a class="nounderline abstract_t">Fink M, Taylor MA. The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci 2001; 251 Suppl 1:I8.</a></li><li><a class="nounderline abstract_t">Bush G, Fink M, Petrides G, et al. Catatonia. II. Treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand 1996; 93:137.</a></li><li><a class="nounderline abstract_t">Peralta V, Cuesta MJ, Serrano JF, Martinez-Larrea JA. Classification issues in catatonia. Eur Arch Psychiatry Clin Neurosci 2001; 251 Suppl 1:I14.</a></li><li><a class="nounderline abstract_t">Daniels J. Catatonia: clinical aspects and neurobiological correlates. J Neuropsychiatry Clin Neurosci 2009; 21:371.</a></li><li><a class="nounderline abstract_t">Penland HR, Weder N, Tampi RR. The catatonic dilemma expanded. Ann Gen Psychiatry 2006; 5:14.</a></li><li><a class="nounderline abstract_t">Fink M. Catatonia: a syndrome appears, disappears, and is rediscovered. Can J Psychiatry 2009; 54:437.</a></li><li><a class="nounderline abstract_t">Trigo M, Crippa J, Hallak J, et al. The complexity of the differential diagnosis in psychiatry exemplified by a catatonic syndrome. Rev Psiquiatr Clin 2001; 28:144.</a></li><li><a class="nounderline abstract_t">Northoff G, Wenke J, Pflug B. Increase of serum creatine phosphokinase in catatonia: an investigation in 32 acute catatonic patients. Psychol Med 1996; 26:547.</a></li><li><a class="nounderline abstract_t">Cottencin O, Warembourg F, de Chouly de Lenclave MB, et al. Catatonia and consultation-liaison psychiatry study of 12 cases. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1170.</a></li><li><a class="nounderline abstract_t">Carroll BT, Anfinson TJ, Kennedy JC, et al. Catatonic disorder due to general medical conditions. J Neuropsychiatry Clin Neurosci 1994; 6:122.</a></li><li><a class="nounderline abstract_t">Taylor MA, Abrams R. Catatonia. Prevalence and importance in the manic phase of manic-depressive illness. Arch Gen Psychiatry 1977; 34:1223.</a></li><li><a class="nounderline abstract_t">Takaoka K, Takata T. Catatonia in high-functioning autism spectrum disorders: case report and review of literature. Psychol Rep 2007; 101:961.</a></li><li><a class="nounderline abstract_t">Wing L, Shah A. A systematic examination of catatonia-like clinical pictures in autism spectrum disorders. Int Rev Neurobiol 2006; 72:21.</a></li><li><a class="nounderline abstract_t">Oldham MA, Lee HB. Catatonia vis-à-vis delirium: the significance of recognizing catatonia in altered mental status. Gen Hosp Psychiatry 2015; 37:554.</a></li><li><a class="nounderline abstract_t">Grover S, Parakh P, Sharma A, et al. Catatonia in systemic lupus erythematosus: a case report and review of literature. Lupus 2013; 22:634.</a></li><li><a class="nounderline abstract_t">Smith JH, Smith VD, Philbrick KL, Kumar N. Catatonic disorder due to a general medical or psychiatric condition. J Neuropsychiatry Clin Neurosci 2012; 24:198.</a></li><li><a class="nounderline abstract_t">Wilson JE, Carlson R, Duggan MC, et al. Delirium and Catatonia in Critically Ill Patients: The Delirium and Catatonia Prospective Cohort Investigation. Crit Care Med 2017; 45:1837.</a></li><li><a class="nounderline abstract_t">Rosebush PI, Mazurek MF. Catatonia and its treatment. Schizophr Bull 2010; 36:239.</a></li><li><a class="nounderline abstract_t">Ungvari GS, Caroff SN, Gerevich J. The catatonia conundrum: evidence of psychomotor phenomena as a symptom dimension in psychotic disorders. Schizophr Bull 2010; 36:231.</a></li><li><a class="nounderline abstract_t">Medda P, Toni C, Luchini F, et al. Catatonia in 26 patients with bipolar disorder: clinical features and response to electroconvulsive therapy. Bipolar Disord 2015; 17:892.</a></li><li><a class="nounderline abstract_t">Sienaert P, Rooseleer J, De Fruyt J. Measuring catatonia: a systematic review of rating scales. J Affect Disord 2011; 135:1.</a></li><li><a class="nounderline abstract_t">Bush G, Fink M, Petrides G, et al. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand 1996; 93:129.</a></li><li><a class="nounderline abstract_t">Northoff G, Koch A, Wenke J, et al. Catatonia as a psychomotor syndrome: a rating scale and extrapyramidal motor symptoms. Mov Disord 1999; 14:404.</a></li><li><a class="nounderline abstract_t">Carroll BT, Kirkhart R, Ahuja N, et al. Katatonia: a new conceptual understanding of catatonia and a new rating scale. Psychiatry (Edgmont) 2008; 5:42.</a></li><li><a class="nounderline abstract_t">Lee JW. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry 1998; 44:499.</a></li><li><a class="nounderline abstract_t">Carroll BT, Goforth HW. Serum iron in catatonia. Biol Psychiatry 1995; 38:776.</a></li><li><a class="nounderline abstract_t">Singerman B, Raheja R. Malignant catatonia--a continuing reality. Ann Clin Psychiatry 1994; 6:259.</a></li><li><a class="nounderline abstract_t">Koek RJ, Mervis JR. Treatment-refractory catatonia, ECT, and parenteral lorazepam. Am J Psychiatry 1999; 156:160.</a></li><li><a class="nounderline abstract_t">Schmider J, Standhart H, Deuschle M, et al. A double-blind comparison of lorazepam and oxazepam in psychomotor retardation and mutism. Biol Psychiatry 1999; 46:437.</a></li><li><a class="nounderline abstract_t">Zaw ZF, Bates GD. Replication of zolpidem test for catatonia in an adolescent. Lancet 1997; 349:1914.</a></li><li><a class="nounderline abstract_t">Thomas P, Rascle C, Mastain B, et al. Test for catatonia with zolpidem. Lancet 1997; 349:702.</a></li><li><a class="nounderline abstract_t">Cottencin O, Danel T, Goudemand M, et al. Catatonia recognition and treatment. Med Sci Monit 2009; 15:CS129.</a></li><li><a class="nounderline abstract_t">Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164:870.</a></li><li><a class="nounderline abstract_t">Fricchione GL. Neuroleptic catatonia and its relationship to psychogenic catatonia. Biol Psychiatry 1985; 20:304.</a></li><li><a class="nounderline abstract_t">Caroff SN, Mann SC, Keck PE Jr. Specific treatment of the neuroleptic malignant syndrome. Biol Psychiatry 1998; 44:378.</a></li><li><a class="nounderline abstract_t">Fink M, Taylor MA. Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30:1182.</a></li><li><a class="nounderline abstract_t">Castillo E, Rubin RT, Holsboer-Trachsler E. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am J Psychiatry 1989; 146:324.</a></li><li><a class="nounderline abstract_t">Fleischhacker WW, Unterweger B, Kane JM, Hinterhuber H. The neuroleptic malignant syndrome and its differentiation from lethal catatonia. Acta Psychiatr Scand 1990; 81:3.</a></li><li><a class="nounderline abstract_t">Keck PE, Arnold LM. The serotonin syndrome. Psychiatr Ann 2000; 30:333.</a></li><li><a class="nounderline abstract_t">Sarkis RA, Coffey MJ, Cooper JJ, et al. Anti-N-methyl-D-aspartate receptor encephalitis: a review of psychiatric phenotypes and management considerations. A report of the American Neuropsychiatric Association Committee on Research. J Neuropsychiatry Clin Neurosci 2017.</a></li></ol></div><div id="topicVersionRevision">Topic 14683 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19884605" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The catatonia syndrome: forgotten but not gone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19884605" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The catatonia syndrome: forgotten but not gone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19884605" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The catatonia syndrome: forgotten but not gone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22135438" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Catatonia from its creation to DSM-V: Considerations for ICD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20075641" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12832234" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Catatonia in psychiatric classification: a home of its own.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21099376" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Catatonia in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15714008" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Catatonia: disappeared or under-diagnosed?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15714008" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Catatonia: disappeared or under-diagnosed?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16219124" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Presentation and frequency of catatonia in new admissions to two acute psychiatric admission units in India and Wales.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20123920" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : ECT in the treatment of a patient with catatonia: consent and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2211547" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8023696" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Benzodiazepines in the treatment of catatonic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18297580" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Catatonic syndrome: importance of detection and treatment with lorazepam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21076339" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Etiopathogenesis of catatonia: generalizations and working hypotheses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21076339" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Etiopathogenesis of catatonia: generalizations and working hypotheses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12958742" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : What catatonia can tell us about "top-down modulation": a neuropsychiatric hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12486486" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18197154" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Brain imaging in catatonia: current findings and a pathophysiologic model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10883714" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Right lower prefronto-parietal cortical dysfunction in akinetic catatonia: a combined study of neuropsychology and regional cerebral blood flow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18197153" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The universal field hypothesis of catatonia and neuroleptic malignant syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11326298" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A missense mutation in a novel gene encoding a putative cation channel is associated with catatonic schizophrenia in a large pedigree.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11776267" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Genetic predisposition and environmental causes in periodic and systematic catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11776268" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Towards the genetic basis of periodic catatonia: pedigree sample for genome scan I and II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12384773" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Periodic catatonia: confirmation of linkage to chromosome 15 and further evidence for genetic heterogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20425278" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Catatonia: diagnosis, classification, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20425278" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Catatonia: diagnosis, classification, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17074935" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Catatonia: subtype or syndrome in DSM?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11776271" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The many varieties of catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8686484" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Catatonia. II. Treatment with lorazepam and electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11776265" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Classification issues in catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19996245" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Catatonia: clinical aspects and neurobiological correlates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16959040" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The catatonic dilemma expanded.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19660165" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Catatonia: a syndrome appears, disappears, and is rediscovered.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The complexity of the differential diagnosis in psychiatry exemplified by a catatonic syndrome</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8733213" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Increase of serum creatine phosphokinase in catatonia: an investigation in 32 acute catatonic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17537561" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Catatonia and consultation-liaison psychiatry study of 12 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8044033" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Catatonic disorder due to general medical conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/911221" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Catatonia. Prevalence and importance in the manic phase of manic-depressive illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18232455" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Catatonia in high-functioning autism spectrum disorders: case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16697289" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A systematic examination of catatonia-like clinical pictures in autism spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26162545" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Catatonia vis-à-vis delirium: the significance of recognizing catatonia in altered mental status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23690443" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Catatonia in systemic lupus erythematosus: a case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22772668" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Catatonic disorder due to a general medical or psychiatric condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28841632" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Delirium and Catatonia in Critically Ill Patients: The Delirium and Catatonia Prospective Cohort Investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19969591" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Catatonia and its treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19776208" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The catatonia conundrum: evidence of psychomotor phenomena as a symptom dimension in psychotic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26643014" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Catatonia in 26 patients with bipolar disorder: clinical features and response to electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21420736" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Measuring catatonia: a systematic review of rating scales.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8686483" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Catatonia. I. Rating scale and standardized examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10348462" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Catatonia as a psychomotor syndrome: a rating scale and extrapyramidal motor symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19724775" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Katatonia: a new conceptual understanding of catatonia and a new rating scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9777183" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Serum iron in catatonia and neuroleptic malignant syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8580236" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Serum iron in catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7647836" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Malignant catatonia--a continuing reality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9892323" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Treatment-refractory catatonia, ECT, and parenteral lorazepam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10435212" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A double-blind comparison of lorazepam and oxazepam in psychomotor retardation and mutism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9217783" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Replication of zolpidem test for catatonia in an adolescent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9078210" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Test for catatonia with zolpidem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19644424" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Catatonia recognition and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17541044" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Neuroleptic malignant syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2858225" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Neuroleptic catatonia and its relationship to psychogenic catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9777166" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Specific treatment of the neuroleptic malignant syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16675086" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2645794" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2184638" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The neuroleptic malignant syndrome and its differentiation from lethal catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The serotonin syndrome</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Anti-N-methyl-D-aspartate receptor encephalitis: a review of psychiatric phenotypes and management considerations. A report of the American Neuropsychiatric Association Committee on Research</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
